Siemens Healthineers shifts medical manufacturing facility from Goa to Bengaluru

M Neelam Kachhap
M Neelam Kachhap
· 3 min read
Siemens Healthineers
André Hartung, Executive Vice President CT and incoming President Diagnostic Imaging;Peter Seitz, Executive Vice President Surgery, Siemens Healthineers;Gerd Hoefner, Managing Director and President, Siemens Healthcare Pvt. Ltd

Bengaluru, India; September 19, 2019: Technological advances are transforming the healthcare industry globally. As a part of its strategy for India, Siemens Healthineers will integrate manufacturing, technology and innovation functions at Bengaluru. Accordingly, the company has setup a new manufacturing facility that is collocated with its R&D center to better leverage synergies while developing offerings aligned to the future needs of its customers.

Explaining the strategic significance of the manufacturing facility at the inauguration ceremony on September 19, 2019 in Bengaluru, André Hartung, Executive Vice President Computed Tomography and incoming President Diagnostic Imaging, Siemens Healthineers said, “Collocating a manufacturing facility with our R&D center in Bengaluru marks a significant step in strengthening our presence in India, which is one of our important markets. It also reflects our enduring commitment to India, where we have been enabling better healthcare outcomes for over 90 years, manufacturing medical devices for 60 years, and advancing software excellence for over 25 years.”

Gerd Hoefner, Managing Director and President, Siemens Healthcare Pvt. Ltd. added, “As Siemens Healthineers is leading the digitalization of healthcare, the collocation of the manufacturing with R&D center is especially important as it will enable us to deliver value to customers faster. Over the years, the R&D center at Bengaluru, has grown into a digital hub for the company accounting for over half of all the software engineering talent within Siemens Healthineers. It is also the largest such center within the company globally.”

Talking about the products that will be made at the new facility, André Hartung said, “The facility will make computed tomography (CT) systems based on our trendsetting Somatom go. platform that we co-created with 500 customers in eleven countries. The new platform combines numerous software-led innovations with our novel detector technologies for radically enhanced workflow efficiency, expanded clinical applicability, improved patient experience, and meeting the financial requirements of healthcare providers.”

Talking about the Cios Fit,  Peter Seitz, Executive Vice President Surgery, Siemens Healthineers stated, “Cios Fit, our latest C-arm was created to address the tough demands of India with high patient loads and the need to perform multiple procedures. It offers clear images on a touchscreen monitor, it is simple to use, and has fewer moving parts for higher reliability. We are very proud that the Cios Fit is designed, developed, and manufactured in India for the world.”

Operations will start immediately in this new ISO13485 (2016) certified state-of-the-art facility, which is spread across 5000 square meters.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk